google-site-verification: googlec7193c3de77668c9.html

FDA approves Simtriyo for treating ADHD in children and adults

[

FDA approves Simtriyo for treating ADHD in children and adults

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.

The once-daily extended-release capsule is the first and only approved norepinephrine, dopamine and serotonin reuptake inhibitor.

The approval is based on four pivotal phase 3 clinical trials, which showed statistically significant and clinically meaningful improvements in ADHD symptoms versus placebo. Across pediatric and adult populations, improvements in ADHD symptoms were seen as early as week 1. In children and adolescents, the most common adverse events included decreased appetite, nausea, rash, headache and abdominal pain. The most common adverse events in adults included headache, decreased appetite, insomnia, nausea, dry mouth and diarrhea.

“Approval of Simtriyo introduces a novel mechanism of action and expands the range of options available to health care professionals and patients,” Lenard A. Adler, M.D., from NYU Langone Health, said in a statement. “Having more therapeutic choices is important because ADHD is a highly individualized condition, and treatment decisions should reflect the unique needs of each patient.”

Approval of Simtriyo was granted to Otsuka Pharmaceutical.

More information

More Information

Key medical concepts

Attention Deficit Hyperactivity Disorderplacebo

Who’s behind this story?


Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news.

Full profile →


Andrew Zinin

Advertisements
Andrew Zinin

Master’s in physics with research experience. Long-time science news enthusiast. Plays key role in Science X’s editorial success.

Full profile →

© 2026 HealthDay. All rights reserved.

Citation:
FDA approves Simtriyo for treating ADHD in children and adults (2026, July 30)
retrieved 30 July 2026
from https://medicalxpress.com/news/2026-07-fda-simtriyo-adhd-children-adults.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Source link

See also  Eczema linked to 28% higher shingles risk in UK primary care analysis

Check Also

AI spots at-risk pregnancies for earlier, more personalized prenatal care

[ Credit: RDNE Stock project from Pexels Artificial intelligence (AI) may help identify women and …

Why Canada’s sunburn problem keeps getting worse

[ Credit: Unsplash/CC0 Public Domain Scroll through social media and you will encounter a strange …

Vaping best way to quit smoking, new study finds

A team looked at 80 major trials involving nearly 30,000 people and found that nicotine …

Leave a Reply

Available for Amazon Prime